Prudential PLC Bei Gene, Ltd. Transaction History

Prudential PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	SELL	$125.51 - $229.3 $279,008 - $509,733	-2,223 Reduced 45.94%	2,616 $575,000
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $353,619 - $542,609	2,683 Added 124.44%	4,839 $652,000
Q2 2022 Aug 12, 2022	BUY	$121.11 - $216.05 $261,113 - $465,803	2,156 New	2,156 $349,000
Q4 2019 Feb 13, 2020	SELL	$115.78 - $208.34 $1.73 Million - $3.11 Million	-14,937 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$120.61 - $148.29 $1.8 Million - $2.22 Million	14,937 New	14,937 $1.82 Million

253

45.3M

292K

119K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.5B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of Prudential PLC, based on Form 13F filings with the SEC.

Stay updated on Prudential PLC with notifications on news.